
Hypertension
Latest News
Video Series

Latest Videos
Shorts





Podcasts
CME Content
More News

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

An individual participant data meta-analysis found antihypertensive therapy reduced cardiovascular events only in patients with at least 80% medication adherence.

United Therapeutics' ralinepag NDA rests on phase 3 ADVANCE OUTCOMES data showing a 55% reduction in clinical worsening versus placebo.

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

John Giacona, PhD, PA-C, discusses the cardiology perspective on screening for and managing pulmonary hypertension in interstitial lung disease.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

Abbas Zaidi, MD, discusses his recent study providing 5 pain points and 5 suggested improvements for the pediatric hypertension treatment flow.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Diana Varghese, MD, discusses her recent study noting a 9% prevalence of PA among patients with incident hypertension and providing targets for further screening strategies.






































































